KOS - Iovance Biotherapeutics Logitech International leads premarket losers' pack

Corbus Pharmaceuticals CRBP -31% as lenabasum flunks mid-stage cystic fibrosis study.Iovance Biotherapeutics IOVA -20% as it has not reached agreement with the FDA on the required potency assays to fully define its tumor-infiltrating lymphocyte therapy lifileucel in metastatic melanoma.Axovant Gene Therapies AXGT -12% after selectively reporting gene therapy data in Parkinson's.Artelo Biosciences (ARTL) -11%.Inpixon (INPX) -7% Nanotron Purchase Agreement.Greenpro Capital (GRNQ) -6%.Logitech International (LOGI) -6%.Kosmos Energy (KOS) -5%.

For further details see:

Iovance Biotherapeutics, Logitech International leads premarket losers' pack